Targets › NY-ESO-1
7 programs from 6 companies in 8 trials: 6 Phase 1, 1 Phase 3, 1 Phase 2; Oncology; next expected readout Nov 2026.
Open in Phaseline: the race on NY-ESO-1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Takara Bio | TBI-1301 NY-ESO-1 directed CAR-T cell therapy | NY-ESO-1 | Phase 3 | Synovial Sarcomas; NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients | Mar 2032 |
| Jonsson Comprehensive Cancer Center | dendritic cell vaccine therapy NY-ESO-1-157-165 peptide pulsed dendritic cell vaccine | NY-ESO-1 | Phase 2 | Malignant Neoplasm | Nov 2027 |
| M.D. Anderson Cancer Center | NY-ESO-1 TCR/IL-15 NK NY-ESO-1 T-cell receptor (TCR)-engineered natural killer cells with IL-15 co-expression | NY-ESO-1, IL15 | Phase 1 | Synovial Sarcoma | Nov 2026 |
| Guangzhou FineImmune Biotechnology | Super1 TCR-T T-cell receptor engineered T cell targeting NY-ESO-1 | NY-ESO-1 | Phase 1 | Sarcoma | Apr 2027 |
| TCRCure Biopharma | TC-N201 cells T cells genetically engineered with a TCR targeting NY-ESO-1 | NY-ESO-1 | Phase 1 | Advanced Solid Tumors | Nov 2027 |
| M.D. Anderson Cancer Center | Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cord blood-derived NK cells transduced with NY-ESO-1 T-cell receptor and IL-15 | NY-ESO-1, IL15 | Phase 1 | Relapsed/Refractory Myeloma | Aug 2028 |
| Roswell Park Cancer Institute | Genetically Engineered NY-ESO-1-specific T Lymphocytes Genetically engineered T cells targeting NY-ESO-1 tumor-associated antigen | NY-ESO-1 | Phase 1 | Recurrent Fallopian Tube Carcinoma | Mar 2032 |
Synovial Sarcomas (1) NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients (1) Relapsed/Refractory Myeloma (1) Advanced Solid Tumors (1) Sarcoma (1) Recurrent Fallopian Tube Carcinoma (1) Malignant Neoplasm (1) Synovial Sarcoma (1)
mixed (5), protein or peptide (1), small molecule (1)
M.D. Anderson Cancer Center (2) Takara Bio (1) TCRCure Biopharma (1) Guangzhou FineImmune Biotechnology (1) Roswell Park Cancer Institute (1) Jonsson Comprehensive Cancer Center (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.